Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional Profiling of NASH mouse models

ABSTRACT: Transcriptional Profiling of NASH mouse models

PROVIDER: PRJNA683606 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13218900_1.fastq.gz	Fastqsanger.gz
	SRR13218900_2.fastq.gz	Fastqsanger.gz
	SRR13219000_1.fastq.gz	Fastqsanger.gz
	SRR13219000_2.fastq.gz	Fastqsanger.gz
	SRR13218901_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 352

Similar Datasets

Transcriptional Profiling of NASH mouse models

Project description:We performed RNA-seq of livers obtained from 2 different NASH mouse models

2021-07-01 | GSE162863 | GEO

Transcriptional profiling of liver, neutrophils and T cells from a mouse model of NASH-HCC

Project description:Transcriptional profiling by bulk RNA sequencing of murine livers or sorted immune cells, from DEN ALIOS NASH-HCC mouse model. Mice treated with CXCR2i (AZD5069) monotherapy, anti-PD1 monotherapy, or combination CXCR2i, anti-PD1 treatment. Published in doi: 10.1136/gutjnl-2021-326259

2023-03-22 | GSE227620 | GEO

Transcriptional profiling of diffuse large B-cell lymphoma mouse models

Project description:Transcriptional profiling of diffuse large B-cell lymphoma mouse models

| PRJNA811583 | ENA

Transcriptomics analysis of in vitro NASH models unveils potential adverse effect of elafibranor

Project description:Non-alcoholic steatohepatitis (NASH) is a life-threatening liver disease for which no drug has been approved. We have previously shown that human-derived hepatic in vitro models can be used to mimic key cellular mechanisms involved in the progression of NASH. In the present study, we first assess the predictive capacity of different in vitro models and then investigate how the reduction of NASH-specific parameters upon treatment with elafibranor, a PPAR-α/δ agonist, correlates with clinical NASH-resolution obtained through bariatric surgery. Whole genome transcriptomics analyses revealed that in vitro NASH models based on primary human hepatocytes (PHH), HepaRG and human skin stem cell-derived hepatic progenitors (hSKP-HPC) exhibit up to 35% overlap with publicly available datasets of liver biopsies of 4 cohorts of NASH patients. Exposure of the in vitro NASH models to elafibranor partially reverses these human-specific transcriptional NASH signatures, with the hSKP-HPC-derived NASH model showing the most sensitive response. NASH-specific transcriptomic changes observed in patients that underwent bariatric surgery correlated with the changes observed in the in vitro NASH models exposed to the PPAR-α/δ agonist. PPARGC1A, PPARA and SIRT1 are shared upstream regulators in the PHH-, HepaRG- and hSKP-HPC NASH models exposed to elafibranor. Activation of these upstream regulators increases the expression of ANGPTL4, PDK4 and PLIN2, while this does not occur in patients that underwent bariatric surgery, suggesting an adverse effect on lipid metabolism. In conclusion, pathologic and therapeutic (anti-)NASH-specific transcriptional responses can be mimicked in PHH, HepaRG and hSKP-HPC, while the latter most sensitively responds to drug testing. PPAR-α/δ agonism adversely modulates pro-steatogenic genes which deserves attention in further studies.

2022-03-16 | GSE166186 | GEO

Transcriptional changes in mouse models in SCA3

Project description:Transcriptional changes in mouse models in SCA3

| PRJNA482631 | ENA

mARC1 knockdown protects liver from diet-induced NASH in mouse

Project description:Human genetic studies have identified several MARC1 variants as protective against non-alcoholic fatty liver diseases (NAFLD). The MARC1 variants are associated with reduced lipid profiles, liver enzymes, and liver-related mortality. However, the role of mitochondrial amidoxime reducing component 1 (mARC1), encoded by MARC1, in NAFLD is still unknown and the therapeutic potential of this target has never been developed. Given that mARC1 is mainly expressed in hepatocytes, we developed an N-acetylgalactosamine conjugated mouse mARC1 siRNA to address this. In ob/ob mice, knockdown of mARC1 in mouse hepatocytes resulted in decreased liver weight, serum lipid enzymes, low-density lipoprotein cholesterol, and liver triglycerides. Loss of mARC1 also improved the lipid profiles and attenuated liver pathological changes in two diet-induced nonalcoholic steatohepatitis (NASH) mouse models. A comprehensive analysis of mARC1-deficient liver in NASH by metabolomics, proteomics, and lipidomics showed that mARC1 knockdown partially restored metabolites and lipids altered by diets. Taken together, loss of mARC1 protects mouse liver from NASH, suggesting a potential therapeutic approach of NASH by downregulation of mARC1 in hepatocytes.

2023-04-28 | MSV000091820 | MassIVE

Transcriptional profiling of liver, neutrophils and T cells from a mouse model of NASH-HCC

Project description:Transcriptional profiling of liver, neutrophils and T cells from a mouse model of NASH-HCC

| PRJNA945918 | ENA

Cell Type-Resolved Transcriptional Profiling of NASH and liver fibrosis

Project description:Cell Type-Resolved Transcriptional Profiling of NASH and liver fibrosis

| PRJNA683628 | ENA

Ribosome profiling experiments of LRRK2 mouse models

Project description:Ribosome profiling experiments of LRRK2 mouse models

| PRJNA705181 | ENA

The FLS (Fatty liver Shionogi) mouse, liver with non-alcoholic steatohepatitis (NASH)

Project description:Comparison between livers of FLS mice and livers of DS (DD shionogi) mice We used FLS mice as model animals of human NASH, while DS mice as control animals. FLS mice develops NASH spontaneously. DS mouse strain is a sister strain of the FLS mouse strain. We compared RNA from pooled livers of three FLS mice and three DS mice at 19 weeks. NASH in livers from FLS mice was confirmied pathologically while simple steatosis of DS mouse livers confirmed.

2013-03-30 | E-GEOD-45624 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data